Published: 22 June 2016
Author(s): F. Santilli, A. Boccatonda, G. Davì
Issue: June 2016
Section: Review Article

Growing evidence suggests the beneficial effect of aspirin against some types of cancer, particularly of the gastrointestinal tract, and it has been provided for an effect both in cancer prevention as well as in survival improvement of cancer patients. Aspirin benefits increase with duration of treatment, especially after 10years of treatment. The inhibition of platelet activation at sites of gastrointestinal mucosal lesions could be the primary mechanism of action of low-dose aspirin. Indeed, the formation of tumor cell-induced platelet aggregates may favor immune evasion, by releasing angiogenic and growth factors, and also by promoting cancer cell dissemination.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.